Prostate cancer patients treated with zoledronic acid suffer renal impairment
June 30th, 2009 Posted in prostate cancer risksAccording to a report by Dr. Oh and colleagues in the online version of Cancer, nearly one-quarter of prostate cancer (CaP) patients treated with zoledronic acid (ZA) suffer renal impairment
ZA is an intravenous bisphosphonate given to decrease skeletal related events in CaP patients with bone metastases. In a phase III trial, ZA was associated with renal impairment in 17% of cases. The present study is the first observational study that quantifies the rate or renal impairment and identifies associated risk factors.